30 completed, 15 terminated, 7 recruiting, 4 active not recruiting. 43 Phase 2, 14 Phase 3, 9 Phase 1, 4 Phase 4, 2 Not applicable.
Follow Mycophenolate Mofetil (MMF): new trials by email Literature Review of Mycophenolate Mofetil (MMF) trials Research Report on Mycophenolate Mofetil (MMF)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation Hematopoietic Cell Transplantation, Cyclophosphamide, Tacrolimus - Graft -Versus-host-disease | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 72 | 2026-11-01 | 2026-09-08 |
| Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI), Fludarabine, Cyclophosphamide - Acute Myeloid Leukemia, Myeloproliferative Neoplasm | Phase 2 | Not yet recruiting | Stanford University | 30 | 2026-11-01 | 2026-09-30 |
| Efficacy and Safety of Mycophenolate Mofetil in Refractory IgA Nephropathy Mycophenolate Mofetil (MMF), Prednisolon - IgA Nephropathy | Phase 2 | Not yet recruiting | Shaheed Suhrawardy Medical College and Hospital | 104 | 2026-09-01 | 2026-08-25 |
| PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure methoxsalen, Extracorporeal photopheresis (ECP), Vedolizumab - Colitis, Hepatitis | Phase 2 | Not yet recruiting | Therakos LLC | 112 | 2026-07-01 | 2026-06-02 |
| Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies Fludarabine, Intermediate-dose Total Body Irradiation (TBI), Post-transplant Cyclophosphamide (PTCy) - Allogeneic Stem Cell Transplant Recipient | Phase 2 | Recruiting | Hackensack Meridian Health | 209 | 2026-01-06 | 2026-03-23 |
| The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment Glucocorticoids, belimumab, Telitacicept - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 2 | Recruiting | Nanjing University School of Medicine | 50 | 2025-12-08 | 2026-03-12 |
| Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation Attenuated-dose Cyclophosphamide, High-dose Cyclophosphamide, Sirolimus - Hematological Malignancies, Graft-versus-Host Disease (GVHD) | Phase 2 | Recruiting | University of Nebraska | 126 | 2025-06-23 | 2026-10-09 |
| A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203) Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux) - Graft-versus-host Disease (GVHD) | Phase 3 | Recruiting | Incyte Corporation | 572 | 2025-04-02 | 2026-10-22 |
| A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome Allogeneic HSCT, Busulfan test dose, Mycophenolate mofetil (MMF) - Immunodeficiency, Hematopoietic Stem Cell Transplantation | Phase 2 | Recruiting | National Cancer Institute (NCI) | 54 | 2023-02-23 | 2026-10-16 |
| Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders Fludarabine, Dexamethasone, Cyclophosphamide - Stem Cell Transplantation | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2022-03-02 | 2023-09-21 | |
| Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Melphalan - Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies | Phase 1 | Active not recruiting | Stanford University | 66 | 2021-09-07 | 2026-05-12 |
| A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation TCD601, Tacrolimus (TAC), Corticosteroids (CS) - Kidney Transplantation | Phase 2 | Terminated | ITB-Med LLC | 33 | 2021-06-06 | 2026-03-12 |
| A Dose Escalation Study in de Novo Renal Transplantation TCD601, Tacrolimus (TAC), Corticosteroids (CS) - Kidney Transplantation | Phase 2 | Completed | ITB-Med LLC | 13 | 2021-05-26 | 2025-02-27 |
| A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD) satralizumab, azathioprine (AZA), mycophenolate mofetil (MMF) - Neuromyelitis Optica Spectrum Disorder | Phase 3 | Completed | Hoffmann-La Roche | 119 | 2021-03-02 | 2024-12-27 |
| Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity Busulfan test dose, Fludarabine, Busulfan - Lymphoproliferative Disorders, Autoimmune Lymphoproliferative | Phase 2 | Recruiting | National Cancer Institute (NCI) | 66 | 2020-09-22 | 2026-10-19 |
| Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML Clofarabine, Fludarabine, Busulfan - Acute Myeloid Leukemia | Phase 2 | Terminated | Milton S. Hershey Medical Center | 2 | 2020-06-03 | 2023-09-14 |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation Vorinostat, Blood and Marrow Transplant (BMT), Tacrolimus (or cyclosporine) - Hematologic Diseases, Acute Leukemia in Remission | Phase 1 / Phase 2 | Active not recruiting | University of Michigan Rogel Cancer Center | 43 | 2020-02-04 | 2026-01-27 |
| Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Fludarabine (FLU), Cyclophosphamide (CY), Total Body Irradiation (TBI) - Acute Myeloid Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Active not recruiting | Masonic Cancer Center, University of Minnesota | 22 | 2019-01-02 | 2026-01-06 |
| Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS) - Kidney Transplantation | Phase 2 | Completed | Novartis Pharmaceuticals | 418 | 2018-11-28 | 2026-03-23 |
| Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation Total body irradiation (TBI), Anti-thymocyte globulin (ATG), Tacrolimus - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2 | Completed | Stanford University | 22 | 2018-11-05 | 2023-12-12 |
Showing 20 of 66. Sign in to see all of them.
Graft vs Host Disease (10) · Hodgkin Disease (10) · Leukemia, Myeloid, Acute (10) · Lymphoma, Non-Hodgkin (10) · Myelodysplastic Syndromes (10) · Hematologic Neoplasms (7) · Leukemia (6) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Glomerulonephritis, IGA (5) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (5) · Lymphoma (5) · Bronchiolitis Obliterans Syndrome (3) · Lupus Nephritis (3) · Lymphoma, Large B-Cell, Diffuse (3)
Stanford University (7) · Novartis Pharmaceuticals (6) · Bristol-Myers Squibb (4) · Hoffmann-La Roche (4) · M.D. Anderson Cancer Center (3) · National Cancer Institute (NCI) (3) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (3) · Astellas Pharma Global Development, Inc. (2) · ITB-Med LLC (2) · Incyte Corporation (2) · Medical College of Wisconsin (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · University of Nebraska (2) · Augusta University (1) · Dana-Farber Cancer Institute (1)
United States (50) · Germany (8) · United Kingdom (8) · Canada (7) · France (7) · Spain (7) · China (6) · Italy (6) · Brazil (5) · Argentina (4) · Australia (4) · Belgium (4) · Hungary (4) · Japan (4) · South Korea (4)
Neal Flomenberg, MD (3) · Dolores Grosso, DNP, CRNP (2) · Robert Lowsky (2) · Adetola A Kassim, MD (1) · Ali Naji, PhD (1) · Amin Alousi, MD (1) · Andrew Posselt, MD, PhD (1) · Anping Xu, MD (1) · Antonio Pagliuca, MBBS, MA, FRCP, FRCPath (1) · Bernhard Hering, MD (1) · Bhavisha A Patel, M.D. (1) · Camillo Ricordi, MD (1)
PMID 38864363, PMID 16192477, PMID 19423725, PMID 19933596, PMID 20039429, PMID 20528878, PMID 21080348, PMID 21868572, PMID 22087680, PMID 22694733, PMID 22694755, PMID 22806274, PMID 22922564, PMID 23009139, PMID 23529285, PMID 23866828, PMID 24504810, PMID 24607552, PMID 25041339, PMID 26146806, PMID 26729448, PMID 26867033, PMID 26888217, PMID 29316837, PMID 31509331, PMID 32556286, PMID 32683127, PMID 33287583, PMID 33635333, PMID 34260836, PMID 35363318, PMID 35907408, PMID 36251488, PMID 37595058, PMID 37703908, PMID 37883803, PMID 38299639, PMID 38493482, PMID 38993854, PMID 39042770, PMID 40118141, PMID 40472328, PMID 40561385, PMID 40743487, PMID 41175032, PMID 41370196, PMID 42049986, PMID 42180389, PMID 42784255
2004 (1), 2015 (1), 2016 (1), 2017 (1), 2019 (1), P30CA014520 (1), U10CA021115 (1), U10HL069294 (1), U24CA076518 (1), UL1TR002240 (1)